Rhythm Pharmaceuticals, Inc. RYTM
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -13.52%
- 1 year
- -17.21%
- Open
- 93.48
- Prev close
- 93.07
- Mkt cap
- 6.35B
- Vol
- 431.66K
- Avg vol
- 659.59K
- EPS
- -3.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 91.42
- High
- 95.60
- Forward P/E
- -147.03
- Beta
- 2.01
- Short ratio
- 13.64
- Inst. own
- 115.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 97.50
- 200-d avg
- 97.20
- 1y target
- 140.53
5D chart
Signals (130)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
5 days ago zacks.com
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago defenseworld.net
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-two ratings firms that are covering the stock,…
1 week ago benzinga.com
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.37% on an annualized basis producing an average annual return of 51.51%. Currently, Rhythm Pharmaceuticals…
1 week ago globenewswire.com
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with…
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
-
2 weeks ago benzinga.com
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.
2 weeks ago globenewswire.com
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan…
2 weeks ago zacks.com
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know
Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $155 to $159.
-
3 weeks ago benzinga.com
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 38.46% on an annualized basis producing an average annual return of 50.82%. Currently, Rhythm Pharmaceuticals…
1 month ago prnewswire.com
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)…
-
1 month ago benzinga.com
Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With Acquired Hypothalamic Obesity
IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS), or genetically…
1 month ago globenewswire.com
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with…
1 month ago defenseworld.net
David Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CEO David Meeker sold 50,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The shares were sold…
1 month ago defenseworld.net
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $97.67 and…
1 month ago seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago globenewswire.com
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses…
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals…
2 months ago benzinga.com
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals…
-
2 months ago benzinga.com
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.
2 months ago 247wallst.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Baozun, Commerce Bancshares, Element Solutions, Evolution Petroleum, Petrobras, Rythm Pharmaceuticals, Terawulf, UMB Financial, Workday, and More
NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh…
2 months ago defenseworld.net
Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM
Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange…
2 months ago fool.com
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Duquesne Family Office has beefed up its healthcare holdings.
-
2 months ago benzinga.com
Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today…
2 months ago globenewswire.com
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
2 months ago fool.com
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
2 months ago seekingalpha.com
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise
Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and…
2 months ago globenewswire.com
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with…
2 months ago marketbeat.com
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
Rhythm Pharmaceuticals NASDAQ: RYTM is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through…
2 months ago benzinga.com
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.
2 months ago benzinga.com
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.
2 months ago benzinga.com
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to…
-
2 months ago benzinga.com
Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses…
-
2 months ago benzinga.com
Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week
Eleven patients with acquired HO were enrolled in the ongoing, open-label trial. Key preliminary findings include:-11.6% reduction in mean BMI from baseline (n=7) after 16 weeks of RM-718;RM-718…
-
3 months ago benzinga.com
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145
JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.
-
3 months ago benzinga.com
Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melanocortin-4 Receptor Agonist, In Patients With Acquired Hypothalamic Obesity Have Been Published In The New England Journal Of Medicine
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.
-
4 months ago benzinga.com
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.
-
4 months ago benzinga.com
Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual Meeting
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
4 months ago benzinga.com
Why Is Rhythm Pharma Stock Jumping Today?
Rhythm Pharma Phase 2 data showed improvements in BMI, body composition, hunger symptoms, and behavior in PWS patients.
-
4 months ago benzinga.com
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $144 to $155.
-
4 months ago benzinga.com
Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in…
-
4 months ago benzinga.com
Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ET
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
-
5 months ago benzinga.com
Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algorithm For Bardet-Biedl Syndrome
"Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria," was published in the peer-reviewed American Journal of Medical Genetics.This simplified and…